Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy.
暂无分享,去创建一个
J. Armitage | V. Bhatt | S. Holstein | V. Shostrom | A. Berger | L. Maness | Krishna Gundabolu | Z. Al-Kadhimi
[1] V. Bhatt,et al. Treatment Strategies for Therapy-related Acute Myeloid Leukemia. , 2019, Clinical lymphoma, myeloma & leukemia.
[2] H. Kantarjian,et al. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia , 2019, Cancer.
[3] V. Bhatt. Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults with Acute Myeloid Leukemia (AML) , 2019, Blood.
[4] V. Bhatt. Cancer in older adults: understanding cause and effects of chemotherapy-related toxicities. , 2019, Future oncology.
[5] V. Bhatt,et al. Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients. , 2019, Future oncology.
[6] E. Estey,et al. More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[7] V. Bhatt. Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling. , 2019, Cancer treatment reviews.
[8] J. Armitage,et al. Treatment patterns and outcomes of octogenarian patients with acute myeloid leukemia , 2019, American journal of hematology.
[9] M. Jongen‐Lavrencic,et al. Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands. , 2018, Cancer epidemiology.
[10] F. Appelbaum,et al. Early mortality and overall survival of acute myeloid leukemia based on facility type , 2017, American journal of hematology.
[11] E. Estey,et al. Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models , 2016 .
[12] H. Kantarjian,et al. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. , 2016, Clinical Lymphoma, Myeloma & Leukemia.
[13] D. Bourn,et al. Incidence and outcomes for adults diagnosed with acute myeloid leukemia in the north of England: a real world study , 2016, Leukemia & lymphoma.
[14] R. Greil,et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.
[15] C. Reyes,et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States , 2015, Annals of Hematology.
[16] J. Williamson,et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. , 2010, Blood.
[17] H. Kantarjian,et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. , 2012, Blood.
[18] D. Weisdorf,et al. Survival for older patients with acute myeloid leukemia: a population-based study , 2012, Haematologica.
[19] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[20] M. Minden,et al. Outcomes and quality of care in acute myeloid leukemia over 40 years , 2009, Cancer.
[21] Sören Lehmann,et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.